Kylo-12

N/A

Report date: 2025/06/23 16:58:42
NME

Base Information

Drug NameKylo-12
Drug Alias NameKylo-12Kylo12
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein C-III inhibitors
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXiamen Ganbaoli Biopharmaceutical Co LtdHangzhou Hygieia Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXiamen Ganbaoli Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaDyslipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A